The LONGEVITY project

The LONGEVITY project is developing long-acting medicines intended for the prevention of malaria and tuberculosis, as well as a single-injection cure for the hepatitis C virus. New medicines we create will be deployed in low- and middle-income countries (LMICs) where the burden is highest, with an estimated 300 million people infected and more than two million deaths per year.

Our aims

• We will reduce the huge burden unsustainable oral regimens place on patients by reformulating pre-existing medicines as long-acting formulations that require administration far less frequently
• Healthcare programmes will be transformed as we expand global knowledge in long-acting injectable product development, regulation of the technology, and how it should be implemented by healthcare providers
• Our world-leading research in materials chemistry and pharmacology, as well as regulatory expertise and community engagement, will improve quality of care for millions of people on a global scale.

Sign up to our newsletter

To sign up for our newsletters and other relevant information, please complete the form below. 

Any personal information you provide will be held in accordance with The EU General Data Protection Regulation (GDPR). For more information please see our Privacy notice